Guillaume N. Fiches

This study uses CRISPR-Cas13X to target HIV-1 TAR RNA, inhibiting viral reactivation and reducing viral load in infected cells.

This study shows that inhibiting KDM5A/B enhances antitumor innate immune responses and induces KSHV lytic reactivation in KSHV-positive B-cell lymphomas.

This study identifies NAT10 as a suppressor of tumor-intrinsic immunity in HNSCC, showing that its inhibition enhances immune responses and suppresses tumor progression.

This study shows that levosimendan inhibits HIV-1 infection in myeloid cells through RIOK1-dependent mechanisms.

This study shows that KSHV and EBV reduce host m5C RNA methylation via c-Myc to destabilize TRIM25 and promote lytic replication.

This study shows NAT10 suppresses IFN-β transactivation by inhibiting IRF3, thereby promoting viral infection.

The paper identifies PRDM6 as a promoter of tumor progression in HNSCC by modulating immune gene expression using scRNA-seq data and IRIS3 analysis.

The paper shows that SUPT16H, a FACT subunit, interacts with BRD4 to suppress antiviral interferon signaling, and its inhibition enhances IFN responses against multiple viruses.